Imagen de Portada

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Jianhui Zhao, Erxu Xue, Zhanju Liu, Xue Li
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
por: Jianhui Zhao, et al.
Publicado: (2024)

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease
por: Jianhui Zhao, et al.
Publicado: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
por: Jeli Mendoza, et al.
Publicado: (2024)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
por: Isabel Carbery, et al.
Publicado: (2024)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
por: Jessica D. Lee, et al.
Publicado: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
por: Virginia Solitano, et al.
Publicado: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
por: A. B. Fons, et al.
Publicado: (2026)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
por: Sanjay K. Murthy
Publicado: (2026)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
por: Fai Fai Ho, et al.
Publicado: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
por: Suprabhat Giri, et al.
Publicado: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
por: Bharati Kochar, et al.
Publicado: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
por: Cong Dai, et al.
Publicado: (2024)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
por: Jessica A. Fitzpatrick, et al.
Publicado: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
por: Cristina Rubín de Célix, et al.
Publicado: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
por: Anupam Kumar Singh, et al.
Publicado: (2026)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
por: Aurelien Amiot, et al.
Publicado: (2025)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
por: Mathieu Uzzan, et al.
Publicado: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
por: A. B. Fons, et al.
Publicado: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
por: Christian Labenz, et al.
Publicado: (2026)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
por: Chang Liu, et al.
Publicado: (2026)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
por: Brigida Barberio, et al.
Publicado: (2026)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
por: José Luis Rueda García, et al.
Publicado: (2026)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
por: Monica E. W. Derks, et al.
Publicado: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
por: Catherine Z. Tang, et al.
Publicado: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
por: Nina Dominik, et al.
Publicado: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
por: Liang Jiao, et al.
Publicado: (2026)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
por: Jiong Yu, et al.
Publicado: (2024)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
por: Pinelopi Arvaniti, et al.
Publicado: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
por: Juan Macias, et al.
Publicado: (2025)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
por: Maryam Kharal, et al.
Publicado: (2024)

Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk
por: Saad Khan, et al.
Publicado: (2024)

Letter: From Descriptive Epidemiology to Clinical Imperative—Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease
por: DuJiang Yang, et al.
Publicado: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
por: Hong‐Li Liu, et al.
Publicado: (2026)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
por: Eunice Yewon Lee, et al.
Publicado: (2024)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
por: Walter W. Chan, et al.
Publicado: (2026)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
por: Mohamed El‐Kassas, et al.
Publicado: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
por: Purab Patel, et al.
Publicado: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
por: Tamar Schildkraut, et al.
Publicado: (2024)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
por: Yash Hegde, et al.
Publicado: (2026)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
por: Shintaro Akiyama, et al.
Publicado: (2025)